Arrowhead Pharmaceuticals Inc (Arrowhead) is a biotech company that develops and commercializes gene silencing therapeutics. The company utilizes RNA chemistries and TRiM platform to target and silence disease-causing genes. Its pipeline products include ARO-AAT, ARO-APOC3, ARO-ANG3, ARO-PNPLA3, GSK4532990, ARO-C3, ARO-ENaC2, ARO-MUC5AC, ARO-RAGE, ARO-MMP7, ARO-COV, ARO-DUX4, ARO-SOD1, HZN-457, JNJ-3989 and Olpasiran. Arrowhead’s therapeutic areas include hypertriglyceridemia, dyslipidemia, facioscapulohumeral muscular dystrophy, complement-mediated diseases, much-obstructive or inflammatory pulmonary conditions, idiopathic pulmonary fibrosis, liver disease, gout, chronic hepatitis B and cardiovascular disease, among others. The company operates lab facilities in San Diego, California and Madison, Wisconsin, the US. Arrowhead is headquartered in Pasadena, California, the US.
Headquarters
United States of America
Address
177 E Colorado Blvd, Suite 700, Pasadena, California, 91105
Website
arrowheadpharma.com
Telephone
1 626 6964702
No of Employees
397
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ARWR (NASD)
Revenue (2023)
$243.2M
-1%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
-16.6%
(2023 vs 2022)
Market Cap*
$2.3B
Net Profit Margin (2023)
XYZ
-17.8%
(2023 vs 2022)
* As of and is in US$
Arrowhead Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline: | TRiM - Targeted RNAi Molecule |
| ARO-AAT - Alpha-1 Liver Disease | |
| ARO-APOC3 - Hypertriglyceridemia | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In June, the company filed an application for approval to initiate a Phase 1 clinical trial of ARO-SOD1. |
| 2023 | Others | In June, the company hosted a Research & Development Day to discuss progress towards the company’s goal to grow its pipeline of RNAi therapeutics. |
| 2023 | Others | In March, the company received the Fast Track designation from the U.S. Food and Drug Administration for ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome. |
Competitor Comparison
| Key Parameters | Arrowhead Pharmaceuticals Inc | Blueprint Medicines Corp | Denali Therapeutics Inc | BridgeBio Pharma Inc | aTyr Pharma Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Pasadena | Cambridge | South San Francisco | Palo Alto | San Diego |
| State/Province | California | Massachusetts | California | California | California |
| No. of Employees | 397 | 661 | 438 | 392 | 65 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Douglass Given | Chairman | Executive Board | 2010 | 70 |
| Christopher Anzalone, Ph.D | Director; Chief Executive Officer | Executive Board | 2007 | 53 |
| Kenneth Myszkowsk | Chief Financial Officer | Senior Management | 2009 | - |
| Javier San Martin | Chief Medical Officer | Senior Management | 2019 | 57 |
| Patrick O’Brien | Secretary; Chief Networking Officer; General Counsel | Senior Management | 2022 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward